06 Nov, EOD - Indian

SENSEX 80378.13 (1.13)

Nifty 50 24484.05 (1.12)

Nifty Bank 52317.4 (0.21)

Nifty IT 42039.5 (3.99)

Nifty Midcap 100 57355.8 (2.21)

Nifty Next 50 71389.8 (2.28)

Nifty Pharma 22920.35 (1.14)

Nifty Smallcap 100 18906.1 (2.18)

06 Nov, EOD - Global

NIKKEI 225 39480.67 (2.61)

HANG SENG 20538.38 (-2.23)

S&P 5923.29 (2.34)

Login/Signup
LOGIN HERE
Cancel

Thyrocare Technologies Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 539871 | NSE Symbol : THYROCARE | ISIN : INE594H01019 | Industry : Healthcare |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
16-Oct-2024 23-Oct-2024 Quarterly Results Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and half year ended September 30 2024. Financial Results for September 30, 2024 (As Per BSE Announcement Dated on: 23/10/2024)
17-Jul-2024 23-Jul-2024 Accounts Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2024 inter alia to consider and approve Board Meeting Intimation for Consideration and Approval of The Unaudited (Standalone & Consolidated) Financial Results of The Company For The Quarter ended June 30 2024. The Board has, at its meeting held today i.e. July 23, 2024, inter alia, considered and approved the unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2024. (As Per BSE Announcement dated on 23.07.2024)
07-May-2024 14-May-2024 Final Dividend Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 inter alia to consider and approve the Audited (Standalone & Consolidated) Financial Results of the Company for the quarter and financial year ended March 31 2024 and to consider Recommending Final Dividend If any we wish to inform you that the Board has at its meeting held today i.e. May 14, 2024, inter alia, considered and approved the audited financial results (standalone and consolidated) for the quarter and financial year ended on March 31, 2024. Pursuant to Regulation 33(3) of SEBI Listing Regulations, the standalone and consolidated audited financial results for the quarter and financial year ended on March 31, 2024, along with the Audit Reports on said financial results issued by the Statutory Auditors of the Company, are attached as Annexure - A. The Board has recommended a final Dividend of Rs. 18/- per equity share of face value of Rs. 10/- each for the financial year 2023-24, for approval at the ensuing Annual General Meeting. The Board of directors of the Company at their meeting held on May 14, 2024, approved the appointment of Mr. Anandh Sundar and Mr. Nishant Shah as additional director designated as Independent Director wef June 15, 2024 Please find attached herewith Audited financial results for the Quarter and year ended 31 March 2024. The Board has recommended a final dividend for Rs.18/- per share for the financial year 2023-24 for approval at ensuing Annual General Meeting (As per BSE Announcement Dated on 14/05/2024) Newspaper Advertisement - Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 16/05/2024)
24-Jan-2024 01-Feb-2024 Quarterly Results Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2024 inter alia to consider and approve Board meeting intimation for Approval of The Unaudited Financial Results of The Company For The Quarter And Nine Months Ended 31St December 2023. 1. the unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2023. 2. Appointment of Mr. Ankit Brijpuriya as Deputy Company Secretary and Deputy Compliance Officer of the Company w.e.f. February 01, 2024; (As Per BSE Announcement dated on 01.02.2024)
23-Oct-2023 31-Oct-2023 Quarterly Results Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2023 inter alia to consider and approve Board Meeting intimation In continuation of our prior intimation dated October 23, 2023 regarding holding of a meeting of the Board of Directors of the Company ('Board'), we wish to inform you that the Board, at its meeting held today i.e. October 31, 2023, inter alia, considered and approved the unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2023. Financial results for the quarter and half year ended September 30, 2023 (As Per BSE Announcement Dated on 31/10/2023) News Paper Publication (As Per BSE Announcement Dated on 02/11/2023)
26-Jul-2023 01-Aug-2023 Quarterly Results Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2023 inter alia to consider and approve Prior Intimation under Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Appointment of Mr. Alok Kumar Jagnani as Chief Financial Officer of the Company w.e.f August 09, 2023 Unaudited Financial results for the quarter ended June 30, 2023 Outcome of Board meeting for unaudited Financial Results For The Quarter Ended June 30, 2023 (As Per BSE Announcement dated on 01.08.2023)
14-Jul-2023 14-Jul-2023 Change in Directors The Board of Directors of the Company at their meeting held on July 14, 2023, inter-alia approved the appointment of Dr. Prapti Ishwar Gilada and Dr. Harshil Jiten Vora as an additional director designated as an Independent Director of the Company with effect from July 14, 2023.
15-May-2023 23-May-2023 Accounts Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 inter alia to consider and approve Prior intimation under Regulation 29(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 23.05.2023)
01-Apr-2023 07-Apr-2023 Interim Dividend Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/04/2023 inter alia to consider and approve Board Meeting Intimation for declaration of interim dividend if Approved by the Board In continuation to our letter dated April 1, 2023 and in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at their meeting held on today, April 7, 2023, inter allia, have declared an interim dividend at the rate of INR 18/- (Rupees Eighteen only per share), (180% of the face value of INR 10/- each) for the financial year 2022-23. The Board has fixed, Thursday April 20, 2023 as the record date for the purpose of determining the entitlement of shareholders for the interim dividend Corporate Action-for declaration of interim dividend for FY 2022-23. (As Per BSE Announcement dated on 07.04.2023)
17-Jan-2023 03-Feb-2023 Quarterly Results Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve Board Meeting intimation Outcome of board meeting of Thyrocare Technologies Limited held on February 3, 2023 Unaudited financial Results for the quarter and nine months ended on December 31, 2022. (As per BSE Announcement Dated on 03/02/2023) Intimation about inadvertent typographical error in the Outcome of Board Meetings of Thyrocare Technologies Limited ('the Company') submitted to the Stock Exchanges on November 11, 2022 and February 3, 2023 (As Per BSE Announcement dated on 08.03.2023)
02-Nov-2022 11-Nov-2022 Quarterly Results Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve Inter alia to consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter / half year ended September 30 2022 and to consider and decide on payment of Interim Dividend if any for the financial year 2022-23. The Stand-alone and Consolidated unaudited financial results for the Quarter/ Half Year ended September 30, 2022, along with the Limited Review Reports. (As Per BSE Announcement dated on 11.11.2022) Intimation about inadvertent typographical error in the Outcome of Board Meetings of Thyrocare Technologies Limited ('the Company') submitted to the Stock Exchanges on November 11, 2022 and February 3, 2023 (As Per BSE Announcement dated on 08.03.2023)
25-Jul-2022 01-Aug-2022 Quarterly Results Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2022 inter alia to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended we wish to intimate that a meeting of our Board of Directors of the Company will be held on Monday August 01 2022 inter alia to consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter ended June 30 2022. We have already intimated to you about the approval of unaudited financial results for the quarter ended June 30, 2022, by our Board of Directors at their meeting held on August 01, 2022. We wish to inform you that that at this meeting, our Board of Directors also approved the financial results separately prepared for stump period September 02, 2021 to March 31, 2022 (which already forms part of the financial results of the FY 2021-22) for consolidation in the accounts of API Holdings Limited, which is the ultimate holding company of our company. Besides, the Board also approved sharing of any financial details relating to the Company with API Holdings Limited, including unpublished price sensitive information, if any, if so required by them to comply with any statutory requirements. (As Per BSE Announcement Dated on 02.08.2022)
22-Apr-2022 29-Apr-2022 Employee Stock Option Employees Stock Option Plan & Dividend & Audited Results Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2022 ,inter alia, to consider and approve Audited Stand-alone and Consolidated Financial Results of the Company for the quarter / financial year ended March 31, 2022, to consider recommending final dividend, if any, for the financial year 2021-22, and to consider granting of Employee Stock Options to the eligible employees for the financial year ended March 31, 2022. This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the Audited Financial Results (Stand-alone and Consolidated) for the Financial Year ended March 31, 2022 and have also decided to declare an interim dividend at the rate of Rs. 15.00 (Rupees Fifteen only) per share (150% of the face value of Rs. 10/- each) for the financial year 2021-22. The Board has fixed, Thursday 12th May 2022 as the record date for the purpose of determining the entitlement of shareholders for the interim dividend. (As Per BSE Announcement dated on 29.04.2022) Thyrocare Technologies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 29, 2022, inter alia, has decided to declare an interim dividend at the rate of Rs. 15.00 (Rupees Fifteen Only) per share (150% of the face value of Rs. 10/- each) for the financial year 2021-22. (As Per BSE Announcement dated on 30.04.2022)
05-Feb-2022 12-Feb-2022 Quarterly Results Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2022 inter alia to consider and approve The meeting of Board of Directors of the Company will be held on Saturday February 12 2022 to inter alia consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter / nine months ended December 31 2021 and to consider and decide on payment of Interim Dividend if any for the financial year 2021-22. 1. This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Nine months ended December 31, 2021 2. As already intimated, the Company has appointed Mr. Rahul Guha as Managing Director & CEO of the Company. As he will be joining by middle of May 2022, the Board of Directors have, in order to comply with the provisions of Sub-Section 4 of Section 203 of the Companies Act, 2013, appointed Mr. Dharmil Sheth, presently a non-independent, non-executive director, to hold the position of Managing Director with effect from 12-02-2022 till the time Mr. Rahul Guha takes charge as MD and CEO. (As Per BSE Announcement Dated on 12.02.2022)
07-Feb-2022 05-Feb-2022 Change in Directors The Board of Directors of the Company, at their meeting held on Saturday, 05th February, 2022, have approved appointment of Mr. Rahul Guha as the Managing Director & Chief Executive Officer of the Company. He will be joining in May 2022
1 2 3